This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
and you are
over 18
years old
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).

Provided treatments

  • Drug: Lenalidomide
  • Drug: Recombinant human erythropoietin
Tris trial is registered with FDA with number: NCT00910858. The sponsor of the trial is Celgene Corporation and it is looking for 40 volunteers for the current phase.
Official trial title:
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes